Drugs · acquisition-cost intelligence
CycloSPORINE, Modfied
cyclosporine· ingredient cyclosporineOther ophthalmologicals· CYCLOSPORINE 100 mg/1; CYCLOSPORINE 100 mg/mL; CYCLOSPORINE 25 mg/1; CYCLOSPORINE 50 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.71770
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 9 weeks.
2025-01-022026-05-20
Same-ingredient options by acquisition cost
Other cyclosporine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| RESTASIS | $1.52 | +$0.80130 |
| Cyclosporine | $2.35 | +$1.63 |
| Cyclosporine | $5.58 | +$4.87 |
| Restasis MultiDose | $112.33 | +$111.62 |
| VEVYE | $368.89 | +$368.18 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 4
Prior auth 100% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.